Cade Hildreth - BioInformant’s Post

• The collaboration between RoosterBio Inc. and Repligen Corporation aims to address the manufacturing challenges of exosomes and extracellular vesicles (EVs), leveraging their respective expertise in primary cell-derived EV production and purification technologies. • A joint 2023 webinar details the integrated bioprocess, combining RoosterBio’s upstream production methods with Repligen’s downstream processing technologies, to efficiently produce high-quality extracellular vesicles. • Critical process parameters and quality attributes for extracellular vesicle production are discussed, demonstrating the effectiveness of the combined approach in maintaining extracellular vesicle integrity and bioactivity. Some of my favorite points: "As original pioneers of Protein A affinity systems, Repligen’s well-engineered instrument platforms and impeccable know-how to purify complex biologics from conditioned cell culture media (including viral vectors) readily translate into solutions for development and clinic-scale batches of extracellular vesicles." "The collaboration’s common goal was to deliver solutions for the manufacturing of extracellular vesicles using scalable and low shear technologies that enable cost-effective commercialization of advanced therapies." "While the bioproduction of therapeutic exosomes / extracellular vesicles isn’t quite magic (yet?), there’s certainly a satisfying wonderment to watch the finest biological, engineering, and professional chemistries combine to brew process innovation progress." We're making MAGIC happen! ✨ Read the blog and watch the webinar to see the data!

Streamline your 2D and Bioreactor cell expansion needs from R&D to clinical manufacturing with RoosterNourish™ bioprocess media. RoosterNourish is optimized to eliminate media exchanges, accelerate research and product development timelines, and reduce associated costs by up to 60%. RoosterBio Inc. is offering 20% off all eligible orders* of RoosterNourish-MSC, RoosterNourish-MSC-XF, and its 3D Bioreactor Media Kit from now until the end of October.   Also, qualifying orders over $4,000 can add one free vial of RoosterVial™-Exosomes, available from multiple tissue sources and manufactured with its standardized 3D bioreactor processes. Use these codes at checkout to save: https://lnkd.in/gbqHgZQ7 SAVE 20% ON EXPANSION MEDIA: MED20R9 ADD A FREE VIAL OF EXOSOMES: EXO4FR3 #cellculture #cellmedia #bioreactor #exosomes #research Kim Hastings

Streamline your 2D and Bioreactor cell expansion needs from R&D to clinical manufacturing with RoosterNourish™ bioprocess media. RoosterNourish is optimized to eliminate media exchanges, accelerate research and product development timelines, and reduce associated costs by up to 60%. RoosterBio Inc. is offering 20% off all eligible orders* of RoosterNourish-MSC, RoosterNourish-MSC-XF, and its 3D Bioreactor Media Kit from now until the end of October.   Also, qualifying orders over $4,000 can add one free vial of RoosterVial™-Exosomes, available from multiple tissue sources and manufactured with its standardized 3D bioreactor processes. Use these codes at checkout to save: https://lnkd.in/g-uRCTCT SAVE 20% ON EXPANSION MEDIA: MED20R9 ADD A FREE VIAL OF EXOSOMES: EXO4FR3 #cellculture #cellmedia #bioreactor #exosomes #research Kim Hastings

Single Use Bioreactors Market Size estimated to reach $10.0 billion by 2028. 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐭𝐡𝐞 𝐅𝐫𝐞𝐞 𝐏𝐃𝐅 𝐒𝐚𝐦𝐩𝐥𝐞 𝐚𝐭 https://lnkd.in/dzUk4cC3 The size of global single use bioreactors market in terms of revenue was estimated to be worth $4.2 billion in 2023 and is poised to reach $10.0 billion by 2028, growing at a CAGR of 19.0% from 2023 to 2028.  The North American market is projected to contribute the largest share for the single use bioreactors industry. 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬: Sartorius Danaher Corporation Thermo Fisher Scientific Merck Getinge Eppendorf Entegris Avantor Corning Incorporated Kuhner shaker TECNIC Bioprocess Equipment Manufacturing PBS Biotech SATAKE MULTIMIX G&G Technologies ABEC bbi-biotech GmbH REPROCELL Cellexus Distek, Inc. OmniBRx Biotechnologies Pvt Ltd New Horizon BIOTECHNOLOGY GPC Biotech AG GPC Bio USA Meissner FILTRATION PRODUCTS Cell Culture Company #SingleUseBioreactors #SingleUseBioreactorsMarket

Process Intensification is a key strategy in helping #biotech manufacturers get the most out of their existing assets - and successfully navigate a highly dynamic drug market. Really enjoyed this insightful discussion with #pharmaceutical industry leaders hosted by BioPhorum Technology Strategy.

For biotech leaders and visionaries, the comprehensive roadmap offered by RoosterBio’s hMSCs, expansion media, and bioreactor feed in combination with the PBS Biotech #Bioreactor Platform can guide clinical manufacturing with precision and efficacy from early phase clinical trials to full-scale commercialization. Check out the article below to join the conversation on the potential transformative impact powerful collaborations like this can have on #biotech advancements and patient care. 🔗 https://lnkd.in/e4mPiNig #cellandgenetherapy #regenerativemedicine #biotechnology #advancedtherapies #celltherapymanufacturing

Greetings everyone, Recently I had an inspiring visit to Sartorius, where I explored cutting-edge advancements in bioprocessing technology! Key Takeaways: Single-Use Bioreactors: Insight into their pivotal role in both upstream and downstream processes, essential for modern biomanufacturing in the pharmaceutical industry. Multi-Parallel Bioreactors: Hands-on experience with Ambr systems (Ambr 15 Cell Culture, Ambr 250 Modular), showcasing flexibility and scalability in experimental setups. Bench-Top & Rocking Motion Bioreactors: Explored various types designed for specific process needs. MODDE 13.1 Software Training: Practical session on Design of Experiments (DoE), transforming theory into hands-on knowledge. TFF Systems and Filter Integrity Testing: Gained valuable knowledge about key tools for process filtration and integrity verification. Sartorius’s contributions to the pharmaceutical industry are truly remarkable. Their bioreactors, such as the Ambr 15 and Ambr 250, streamline experimental setups with precision and scalability, advancing biologics development. Instruments like high-precision filters, pH meters, weighing machines, and laboratory equipment ensure accuracy and reliability at every stage of bioprocessing, fueling innovation in pharmaceuticals. A huge thanks to Vinay Prathap sir , Kathiravan V sir, Bhagyasree Pillai ma'am for training us and Biocon Academy, our mentors Ramgopal Rao S, PhD sir, Salavadi Easwaran sir and Bindu Ajit ma'am for providing me with this enriching experience. A special thanks to David Kent sir for his thorough guidance on these topics. Excited to bring these learnings forward in bioprocessing! #bioprocessing #pharmaceuticals #Sartorius #DoE #innovation #biomanufacturing #biotech

Process Intensification: Reduce biomanufacturing costs whilst saving the planet and providing greater access of medicines to patients.   The Technology Strategy Phorum recently hosted industry thought leaders for a panel discussion on process intensification. Panellists were from Asahi Kasei, Cytiva, Emerson, FUJIFILM Diosynth, Merck & Co, Novo Nordisk, Sartorius and Takeda. We discussed: ·     the definition of Process Intensification (PI) –(tackling high mass demand, Introduction of new technologies, linking unit ops). ·     the benefits of PI (agility, cost reduction, yield, sustainability etc.) ·     the main barriers to progress in PI (risk, business drivers, regulatory, implementing changes while supplying the market.) ·     key unit operations for PI (perfusion bioreactor, multi-column chromatography, viral filtration and inactivation.) ·     activity in the industry in PI. Thank you to all the BioPhorum Technology Strategy members and guests who took part in what was an interesting and important discussion. We only scratched the surface of this topic, so we will likely discuss this again in more depth! Previous publications by BioPhorum covering process intensification and continuous bioprocessing are available to view here: Conti Downstream Bioprocessing roadmap: https://lnkd.in/eRBjN2GZ   Risk assessment blueprint for Conti bio: https://lnkd.in/eVdRund   Control and connectivity paper: https://lnkd.in/efdt4r8d If your organization is a BioPhorum Technology Strategy Phorum member you can access the recording of the panel discussion https://lnkd.in/eppiyxJn If you are not currently a BioPhorum Technology Strategy member and would like to find out more about what we do, please contact us via [email protected] to register your interest.    #biomanufacturing #newtechnology

Aragen Bioscience recently partnered with Sweden-based Getinge to diagnose and trouble-shoot challenges arising during scale-up from bench scale to production scale. In our quest to enhance our capabilities, we've integrated Getinge's state-of-the-art single-use production reactors (SUPRs) into our operations. To meet the demands of larger-scale production runs required for preclinical studies, we embarked on a trial with Getinge. By adopting their 50 L and 250 L SUPRs, we aimed to amplify our production volumes, facilitating faster preclinical production processes. During the trial, Aragen’s model fed-batch process was successfully scaled up from a 2 L STR to 50 L and 250 L SUPRs (Single Use Production Reactors). Unlike conventional multi-use reactors, SUPRs are more efficient because they can be set up instantly and also have a lower risk of cross-contamination. Click here to read the full details of the study https://lnkd.in/ghyTr7QK Meet our team at the upcoming PEGS Boston event from 13th -17th  May, 2024, at Omni Boston Hotel, Sea port, booth no. 710 to discuss how Aragen can use the Getinge SUPRs to accelerate your bioproduction process. Keshav Vasanthavada Lakshman Rajagopalan Subodh Deshmukh #bioreactors #journey #bioproduction #drugmanufacturing #preclinical #sweden #boston #drugdevelopment #events2024 #aragen #endtoendsolutions #largemolecules #biologics #california